News

Vaccine Platform for Pandemic Preparedness and Global Immunization ATLANTA, GA - July 28, 2025 (NEWMEDIAWIRE) - GeoVax Labs, ...
Analysts anticipate Geovax Labs to report an earnings per share (EPS) of $-0.41. Anticipation surrounds Geovax Labs's ...
Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...
GeoVax’s MVA vaccine platform is designed to address gaps in pandemic preparedness and public health resilience, with lead vaccine candidate GEO-CM04S1 currently being evaluated in multiple ...
GeoVax’s advanced MVA manufacturing process directly addresses key gaps cited in the Executive Order, including long permitting timelines, foreign dependence for active pharmaceutical ...
--GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a ...
GeoVax has other ongoing Phase 2 trials assessing GEO-CM04S1 as a primary vaccine for immunocompromised patients and as a durable booster for individuals previously vaccinated with mRNA vaccines.
If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at [email protected]. GeoVax Labs, Inc. is a ...